Abstract
Transgene is developing TG-4010, a second-generation modified vaccinia virus Ankara encoding MUC1 and interleukin-2 for the potential treatment of a variety of cancer types. Phase II trials are underway for non-small-cell lung cancer, metastatic renal cancer and prostate cancer.
MeSH terms
-
Animals
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Cancer Vaccines / genetics
-
Cancer Vaccines / pharmacology
-
Cancer Vaccines / therapeutic use*
-
Clinical Trials, Phase II as Topic
-
Drug Industry / methods*
-
Drugs, Investigational / pharmacology
-
Drugs, Investigational / therapeutic use*
-
Humans
-
Vaccinia virus / genetics
Substances
-
Antineoplastic Agents
-
Cancer Vaccines
-
Drugs, Investigational